Should I Buy RZLT? RZLT 2026 Analysis

Should You Buy Rezolute Inc (RZLT) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

3.300

1 Day change

4.10%

52 Week Range

11.460

Analysis Updated At

2026/04/24

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Rezolute Inc (RZLT) is not a strong buy at the moment for a beginner investor with a long-term strategy. The technical indicators are bearish, and there are no significant positive catalysts or trading signals to suggest immediate upside potential. While the FDA's feedback on its congenital HI program is a positive development, the company's financial performance remains weak, and the stock lacks momentum or strong institutional support. Holding off on investing in RZLT until clearer positive trends emerge would be prudent.

Technical Analysis

The MACD is negative and expanding downward, RSI indicates no clear signal, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level (S1: 3.157) with resistance at R1: 3.768. Overall, the technical outlook is bearish.

Options Data

Bullish

Open Interest Put-Call Ratio

Bearish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

FDA feedback on the congenital HI program suggests recognition of unmet medical needs and potential benefits of Rezolute's treatment. Analyst upgrade by Wedbush with a price target increase to $5.

Neutral/Negative Catalysts

No significant trading trends from hedge funds or insiders. Weak financial performance with negative net income and no revenue growth. Lack of recent news or congressional trading data.

Financial Performance

In Q2 2026, the company reported no revenue growth (0% YoY), a net income of -$22.77M (improved by 44.78% YoY), and an EPS of -0.22. Gross margin remains at 0%. Financial performance remains weak overall.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Wedbush upgraded the stock to Outperform from Neutral with a price target increase from $2 to $5. This upgrade is based on FDA feedback and the potential of the congenital HI program, though with only a modest 30% probability of success.

9 Analyst Rating

Wall Street analysts forecast RZLT stock price to rise

5 Buy

4 Hold

0 Sell

Moderate Buy

Current: 3.300

Low

Averages

6.29

High

Current: 3.300

Low

Averages

6.29

High

Wedbush

Neutral

Outperform

upgrade

$2 -> $5

AI Analysis

2026-03-25

Reason

Wedbush

Price Target

$2 -> $5

AI Analysis

2026-03-25

upgrade

Neutral

Outperform

Reason

Wedbush upgraded Rezolute to Outperform from Neutral with a price target of $5, up from $2.

Wedbush

Yun Zhong

Neutral

Outperform

upgrade

$2 -> $5

2026-03-25

Reason

Wedbush

Yun Zhong

Price Target

$2 -> $5

2026-03-25

upgrade

Neutral

Outperform

Reason

As previously reported, Wedbush analyst Yun Zhong upgraded Rezolute to Outperform from Neutral with a price target of $5, up from $2, based on the update following a Type B meeting with the Food and Drug Administration to discuss the regulatory pathway for ersodetug in congenital hyperinsulinism. The FDA encouraged Rezolute to submit available data from both the randomized, double-blind, placebo-controlled portion of the pivotal Phase 3 sunRIZE study and the ongoing open-label extension portion for an independent evaluation by the FDA. Wedbush sees the FDA's feedback as showing the agency's recognition of both an unmet medical need in congenital HI and potential benefit that ersodetug can bring to patients. The firm has added the congenital HI program back to its valuation, although with a modest 30% probability of success and only revenue in the U.S.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for RZLT

Unlock Now

RZLT Should I Buy

RZLT Should I Buy

Should You Buy Rezolute Inc (RZLT) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch